This phase III clinical trial investigated the efficacy and safety of pembrolizumab as adjuvant therapy for patients with triple-negative breast cancer. The study enrolled 1195 participants diagnosed with stages I through III breast cancer, including triple-negative and low estrogen receptor-positive/HER2 borderline breast cancers, following neoadjuvant chemotherapy. Patients were randomized to receive either 1 year of pembrolizumab administered intravenously or no pembrolizumab.
Key Clinical Findings
The primary objective was to compare invasive disease-free survival in patients with residual disease or positive lymph nodes, specifically examining the PD-L1 positive subset. Secondary objectives included assessing overall survival and distant recurrence-free survival within the PD-L1 positive patient population and evaluating the toxicity and tolerability of pembrolizumab. A behavioral and health outcomes study examined the association between biomarkers and patient-reported outcomes.
Study Duration and Monitoring
Patients were followed for up to 10 years post-randomization, with regular monitoring and data collection throughout the trial period.